• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Markets
    • Venture Capital
  • About
  • Contact

European Union’s Horizon 2020 Program Funding Underwrites Second-Generation Zika Vaccine Candidate Development: Themis Bioscience and ZIKAVAX Consortium Announce Initiation of Phase 1 Zika Vaccine Trial

October 1, 2019 By admin Leave a Comment

Themis Bioscience announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on Themis’ proprietary measles vector platform, which includes exclusively licensed technology from Institut Pasteur. It was initially developed by Institut Pasteur as part of the ZIKAVAX consortium, coordinated by the European Vaccine Initiative (EVI) and including Themis and the Commissariat à l’énergie atomique et aux énergies alternatives (CEA). The four-year collaborative project covers pre-clinical and clinical development and is funded under the European Union’s Horizon 2020 Research and Innovation Program (H2020 grant agreement No 732432) with an overall budget of €5 million. The Phase 1 program and further development will be run by Themis and this first trial will evaluate the safety and immunogenicity of the candidate in healthy volunteers.

“Zika remains a global health burden with no existing vaccines, a situation exacerbated by the ongoing increase of the geographical areas exposed to the virus,” said Erich Tauber, MD, CEO of Themis Bioscience. “Together with the ZIKAVAX consortium, we have applied the immune modulation potential of our measles vector approach as well as our growing clinical development expertise to provide an urgently needed Zika vaccine. Our long-standing collaborative partnership with the Institut Pasteur has been fundamental in developing this and a number of other innovative vaccine candidates, the first of which has been validated through our Phase 3-ready Chikungunya vaccine.”

Dr Nicola Viebig, Chief Scientific Officer of EVI added: “EVI´s mission to accelerate the development of vaccines for global health crucially depends on bringing together the right partners to leverage synergies. The ZIKAVAX is a good demonstration of these efforts. Based on the in vitro and in vivo data we have gathered within the collaboration, we believe that Themis’ measles vector platform provides a promising approach for developing a safe and efficacious Zika vaccine, which we will further investigate in this clinical study.”

The observer-blinded, randomized trial will investigate the safety and tolerability of the novel Zika vaccine formulation in 48 healthy volunteers. The vaccine will be administered by intra-muscular injection in two different dose levels. Secondary objectives will include optimal dose-finding, immunogenicity and long-term safety evaluation, as well as cell-mediated immunity specific to the Zika antigen.

This is the second Zika program based on Themis’ measles vector platform to enter the clinic. The first Themis-developed Zika program was funded through an InnovateUK grant and clinical evaluation is ongoing. Themis’ lead program is a Phase 3-ready Chikungunya vaccine. The company’s pipeline includes additional earlier-staged vaccines and immuno-oncology development programs. Themis holds an exclusive license from the Institut Pasteur for its measles vector technology.

About Zika
Zika virus is a mosquito-born infectious disease that causes a mild illness in healthy adults, however, Zika virus infection during pregnancy can cause infants to be born with microcephaly. The first association of Zika infection and microcephaly were reported in 2015 in Brazil. Since that time, outbreaks and evidence of transmission have been documented throughout the world with a total of 86 countries and territories currently reporting evidence of mosquito-transmitted Zika infection.

About Themis
Themis is developing immunomodulation therapies for infectious diseases and cancer. Through advanced understanding of immune system mechanisms, the Company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches. Initially focused on preventing infectious diseases, Themis has demonstrated the potential of its versatile platform through the rapid and successful completion of Phase 2 and near-term entry into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Funded to date by leading venture capital firms, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications. The Company will apply its platform and commercial manufacturing capabilities to diseases with high market potential both alone and for its partners. For more information, visit http://www.themisbio.com.

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

With the world’s largest reserves of nickel and a ban on the export of nickel ore, Indonesia is positioning itself as a critical player in the EV industry
The US curbs on China’s semiconductor industry have a significant impact on the Asian semiconductor manufacturing landscape
The Immersive Experience in the Museum World
How insurers thrive in a turbulent market
Leveraging Artificial Intelligence to Drive Cost Savings and Productivity in Uncertain Times
The shipping industry is undergoing a significant change with the influx of new vessels arriving just as the growth of trade is beginning to slow down
Climate change is increasingly affecting the production of beer ingredients

Market Research Media

Streaming video, training, and gaming coming together to form a cohesive and diverse media and entertainment ecosystem
Turn Your Story into a Game: The Art of Gamifying Your Plot
The end of cheap money is redrawing the map of corporate earnings
The Future of Virtual Reality: How VR is Changing Industries
Market Research Media Survey: The State of Streaming Services
Media measurement services provide a holistic view of cross-media consumption
Gen Z ranks top in luxury sales

Secondary Sidebar

Tech Events

Embedded World 2023, March 14-16, 2023, Nuremberg, Germany
The IOT Solutions World Congress and Barcelona Cybersecurity Congress, May 21-23, 2024, Fira de Barcelona’s Gran Via venue
React Summit 2023, June 2 (in-person in Amsterdam) & June 6 (remote), 2023
Blockchaining 2023: The crypto world is facing a crisis of confidence
ScyllaDB Summit 2023 taking place online on February 15-16, 2023

Venture Capital

Gradient, a company specializing in eco-friendly heating and cooling solutions, has raised $18 million in a Series A funding round
The Importance of Diversity and Inclusion in the Workplace
Sequoia Capital announces its $195 Mln dedicated seed fund
Sublime Systems Secures $40 Million Series A to Electrify and Scale Decarbonized Cement Production
actyv.ai Raises Pre-Series A Funding to Fuel Global Expansion, Product Enhancement

Footer

Recent Posts

  • Nel Hydrogen Electrolyser has received a purchase order €12 million for 40 MW of alkaline electrolyser
  • The use of immersive technology in museums is still in its early stages
  • The low tech unemployment rate and hiring activity confirms the long-term demand for tech talent
  • Virgin Orbit and SatRev Sign Launch Services Agreement
  • Harnessing the Power of Innovation for a Better Tomorrow
  • Breaking Down Silos: The Need for Cross-Sector Collaboration in Tackling Global Challenges
  • The SPIE Prism Awards recognized the best new optics and photonics products
  • Netlify has acquired Gatsby
  • Potential for disruption: Conference is the most inefficient way to get information
  • Artificial Intelligence: The Future of Healthcare

App Coding

Platform.sh Secures $140 million in Series D Funding to Support Enterprises in Scaling Fleets of Websites and Applications
monday.com Adds Built-In Monetization Solution to the apps marketplace
NLP techniques are bridging the gap between text documents
Distraction-free coding
Configit Introduces Breakthrough System-Level Configuration Solution

API Coding

How to code an API with ChatGPT
New survey reveals API strategies, concerns as enterprises look to securely free data for business growth
How to teach yourself API coding
What is an API Gateway?
API Security Guide

Blockchaining

Blockchain Technology: Ownership Through Equity Tokenization
Join Our Team as a Blockchain Developer - Revolutionize the Future
Wecan launches a blockchain along with its token and successfully completes its first private pre-sale
What are Non-Fungible Tokens (NFTs)?
What is a blockchain domain?

Event Calendar

eCarExpo, February 3-5, 2023, Stockholm
AHR Expo, the largest HVAC event in North America, February 6-8 2023, Atlanta, Georgia
The Cultural Transformation Business Summit, hosted by Epic Pivot, will take place on February 23, 2023 at The Wond’ry, Vanderbilt University’s Innovation Center
The CannaReg Summit 2023, March 22-23, 2023 in Burlington, VT
INDEX, the world’s largest nonwovens exhibition, takes place on 18-21 April 2023 in Geneva, Switzerland

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT